Skip to main content
Premium Trial:

Request an Annual Quote

Structural Genomix in Research Collaboration with Lilly

NEW YORK, April 21 - Structural GenomiX (SGX) said today that it has entered a research collaboration with Eli Lilly based on its 3D structure determination technology.


SGX will apply its technology to several Lilly drug targets to determine their three-dimensional structures and generate data on compounds that bind to the drug targets. SGX will also install its technology for Lilly in a high-throughput structural biology facility the company is planning for protein engineering, crystallization, and structure determination.


"The financial benefits to SGX of both the research collaboration and the technology transfer arrangements are substantial," said SGX CEO Tim Harris in a statement. "Further, Lilly is committed to implementing SGX's gene-to-structure platform in their drug discovery programs. This is not a proof-of-principle deal."


Lilly has committed to supporting the research collaboration for at least two years, with an option to extend to a third year.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.